Regeneron Pharmaceuticals (REGN) Competitors

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Is AMGN or REGN a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Regeneron Pharmaceuticals pays an annual dividend of $3.52 per share and has a dividend yield of 0.6%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Regeneron Pharmaceuticals pays out 8.9% of its earnings in the form of a dividend. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Does the media prefer AMGN or REGN?

In the previous week, Amgen had 17 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 49 mentions for Amgen and 32 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.33 beat Regeneron Pharmaceuticals' score of 1.19 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	42 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	23 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, AMGN or REGN?

Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in AMGN or REGN?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.8% of Amgen shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend AMGN or REGN?

Amgen currently has a consensus price target of $309.70, suggesting a potential upside of 3.96%. Regeneron Pharmaceuticals has a consensus price target of $817.67, suggesting a potential upside of 36.28%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.30
Regeneron Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	3 Strong Buy rating(s)	2.82

Is AMGN or REGN more profitable?

Regeneron Pharmaceuticals has a net margin of 31.37% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	18.96%	174.71%	13.12%
Regeneron Pharmaceuticals	31.37%	15.06%	11.77%

Which has preferable earnings & valuation, AMGN or REGN?

Regeneron Pharmaceuticals has lower revenue, but higher earnings than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.80	$4.09B	$12.23	24.36
Regeneron Pharmaceuticals	$14.21B	4.47	$4.41B	$39.68	15.12

Summary

Amgen and Regeneron Pharmaceuticals tied by winning 10 of the 20 factors compared between the two stocks.